A study including 68 IBD patients (with only 5 UC patients) reported that VSR was not correlated with treatment failure of anti-TNFα (56), while another study including 99 patients with Crohn’s disease (CD) found that a high VFI:SMI ratio was associated with an increased risk of failing standard doses of ustekinumab (57). Here, TNF is linked to inflammatory bowel disease.